These interferon-stimulate gene+ cDC2s may therefore have therapeutic potential, but we still lack understanding of how cDC2 sub-populations are related and their relative contribution to or against anti-tumour immunity; indeed one study using elegant combinations of genetically modified mice has suggested that, in fact, cDC1 are competent to prime both CD4 and CD8 T cells in tumours [43]. Here, CD8A is linked to neoplasm.